Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.
Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.
Stewart
J P
JP
CRC Department of Molecular Biology, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.
McGown
A T
AT
Prendiville
J
J
Pettit
G R
GR
Fox
B W
BW
Arrand
J R
JR
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000382:microbiology*; D054713:Bryostatins; D002472:Cell Transformation, Viral / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D007783:Lactones / Q000494:pharmacology* / Q000627:therapeutic use; D018942:Macrolides; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D017735:Virus Latency / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects*
D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D013755:Tetradecanoylphorbol Acetate